

Overview of Proper Management of Adrenal Insufficiency

¹Afnan Abdullatif Al-Namankany, ²Bayan Talal Zamil, ³Najwa Ali Alzahrani,
⁴Hanadi Hezam Al-Thobiati

Abstract: Current review was aimed to emphasize the proper management of adrenal insufficiency, we intended to discuss the steps before starting the management, which is very important to establish successful treatment strategy, such diagnostic methods and causes of AI. Comprehensive search was performed using electronic databases as; PubMed, and Embase, to find studies concerning with adrenal insufficiency published with English language, up to, 2017 September. Adrenal insufficiency is a lethal problem; very strong research evidence suggests that long-lasting corticosteroid usage is consistently connected with gotten adrenal insufficiency. Measurement of cost-free lotion or salivary cortisol might be useful when CBG is reduced, but calls for standardization. Adrenal insufficiency is related to minimized quality of life that may be triggered by non-physiological glucocorticoid replacement. DHEA insufficiency is unlikely to play a major role in quality of life of adults, as well as regular replacement is not necessitated.

Keywords: DHEA, Adrenal Insufficiency, CBG.

1. INTRODUCTION

Adrenal insufficiency (AI) is caused by failure of the adrenal cortex to generate cortisol. This failing can result from loss of function of the adrenal glands (ie, primary adrenal insufficiency), which is most regularly caused by autoimmune adrenalitis (Addison's condition) as well as inherited disturbance of glucocorticoid synthesis by congenital adrenal hyperplasia [1,2]. Second adrenal insufficiency is triggered by impaired hypothalamic-pituitary policy of synthesis of adrenal cortisol, primarily triggered by tumors of the hypothalamic-pituitary region as well as their therapy with surgical procedure or radiotherapy [3]. Long-term exogenous glucocorticoid therapy also inevitably causes adrenal insufficiency, with potential reversibility after progressive therapy withdrawal. In Europe, the prevalence of chronic primary adrenal insufficiency has actually boosted from 40 - 70 situations each million individuals in the 1960s [4,5] to 93-- 144 cases per million by the end of the 20th century, [6,7] with an approximated incidence currently of 4 · 4-- 6 · 0 brand-new cases per million population each year [1]. In a collection of 615 patients with Addison's condition, examined in between 1969 as well as 2009, the autoimmune form was detected in 82% of situations, the tuberculosis related type in 9%, as well as various other causes in about 8% of instances [8]. Primary adrenal insufficiency takes place a lot more frequently in females compared to in guys, and can offer at any age, although most often appears between the ages of 30 as well as 50 years [6].

Primary AI is identified by the damaged production of adrenal steroids, consisting of aldosterone, cortisol as well as adrenal androgens. Idiopathic adrenal degeneration by autoimmune devices or consumption account for the majority of instances of grown-up AI, and also such obtained instances of primary AI are called Addison's condition. Congenital kinds of primary AI consist of congenital adrenal hyperplasia, congenital adrenal hypoplasia and also domestic glucocorticoid shortage (FGD) [9]. Secondary AI triggered by sores of the HPA axis causes impaired ACTH synthesis, bring about damaged production of cortisol and adrenal androgens from the adrenal gland. In the case of additional AI, aldosterone production is normally maintained due to the fact that the R-A system is protected. Root causes of additional AI consist of pituitary tumors, lymphocytic hypophysitis, craniopharyngioma, germinoma and also treatments including surgical treatment and also radiation [10].

Current review was aimed to emphasize the proper management of adrenal insufficiency, we intended to discuss the steps before starting the management, which is very important to establish successful treatment strategy, such diagnostic methods and causes of AI.

2. METHODOLOGY

Comprehensive search was performed using electronic databases as; PubMed, and Embase, to find studies concerning with adrenal insufficiency published with English language, up to, 2017 September. several keywords were used in our search strategy such as; “adrenal insufficiency”, “Adison disease,” “Management,” “Therapy” “Treatment”. Moreover, references found in retracted studies were searched for more evidence available.

3. DISCUSSION

• Etiology of adrenal insufficiency:

In primary AI, there is failure of production of all hormones from the adrenal cortex; it is frequently triggered by autoimmune damage in established nations (Table 1) [8,11] AI might take place alone, with other autoimmune conditions (polyglandular autoimmune disorder kind 2 and also polygenic inheritance) or with hypoparathyroidism and mucocutaneous candidiasis (polyglandular autoimmune syndrome kind 1) because of autosomal recessive inheritance of mutations in the AIRE genetics [12].

There is significant rate of interest concerning hereditary tendencies to establish autoimmune adrenal insufficiency, along with the well-known organization of the HLA genotype DR3/4-DQB 1 with type 1 diabetes mellitus and AI. In a research study of 63 patients with type 1 diabetes mellitus and also their relatives, that had positive 21-hydroxylase antibodies, this haplotype was not related to development to frank adrenal insufficiency. Nonetheless, the allele regularity of an additional significant histocompatibility complicated genetics, MICA5.1, was boosted in those that progressed, with a hazards ratio 8.628 (95% self-confidence period 2.029-- 36.696) [13]. This allele encodes an abbreviated protein and also has actually an increased frequency in other autoimmune problems [14,15].

Adrenoleukodystrophy (ALD) is an X-linked recessive problem brought on by mutations in the ABCD1 genetics, resulting in faulty oxidation of very long chain fats (VLCFAs) as well as membrane and organelle dysfunction [16] Current reports drew attention to infectious and also drug-related root causes of adrenal insufficiency. HIV-associated immunosuppression has resulted in resurgence in contagious reasons (e.g. tuberculous as well as CMV adrenalitis) [17]. Agents that may dramatically decrease cortisol synthesis include anti-fungal representatives and also just a single dose of the anesthetic etomidate [18] Unique tyrosine kinase targeting medicines, such as sunitinib, could create AI in pets [19]; human reports are waited for.

Table 1: Causes of primary adrenal insufficiency (PAI)

Cause	Prevalence
Autoimmune destruction	1 in 10,000 [8,11]
Congenital adrenal hyperplasia	1 in 15,000 [11]
X-linked adrenoleukodystrophy	1 in 20,000 men [16]
Drugs inhibiting steroidogenesis	
Infectious	
Hemorrhagic	

• Diagnosis of adrenal insufficiency:

The diagnosis of PAI is commonly based on reduced morning cortisol focus (determined in serum or plasma) as well as verified by reduced stimulated cortisol. DHEAS levels (DHEA less so) that are well below the lower restriction of normal for age and sex are a beneficial preliminary indicator of PAI that must not be overlooked, although they could not be made use of in isolation making the medical diagnosis of PAI due to the fact that degrees may be reduced in some individuals, specifically in older age groups, without PAI. For the most parts, the diagnosis is extremely likely if the cortisol is <140 nmol/L (5 µg/dL)[20]in combination with an ACTH concentration (measured in plasma) elevated more

than 2-fold above the upper limit of the reference interval for the specific assay. An ACTH value > 140 nmol/L (5 μ g/dL) [20] in combination with an ACTH focus (determined in plasma) raised greater than 2-fold over the upper limit of the reference interval for the certain assay. An ACTH value > 66 pmol/L represents an optimum stimulation for cortisol secretion [21,22]. For verification, a corticotropin stimulation examination need to be carried out in many cases unless basic results are definitely indisputable.

The corticotropin excitement test is presently considered the diagnostic "gold standard" for the medical diagnosis of primary (yet not second) adrenal insufficiency because it has been fairly well researched and is confirmed against the insulin resistance test for analysis accuracy [23,24]. This examination is likewise referred to as the cosyntropin test, ACTH test, or brief Synacthen examination; Synacthen is the trade name of tetracosactide, a synthetic peptide consisting of the very first 24 of the 39 amino acids of the endogenous ACTH peptide. Nonetheless, there is still some continuous debate over the definition of the cutoff worth of cortisol after corticotropin stimulation to leave out PAI (see listed below). The test is made use of in professional experiment different procedures, mainly in the duration of the examination treatment, the course of management (im or iv), and also the dose of corticotropin applied [25,26]. Frequently, the common short corticotropin examination is done gauging cortisol degrees before and 30 or 60 minutes after iv (or im) management of 250 μ g corticotropin as bolus injection [27]. The standard-dose (250 μ g) short corticotropin test is an usual diagnostic examination in medical practice with a high degree of recognition. One more variation of the cosyntropin test uses a low-dose 1 μ g of corticotropin for adrenal stimulation. Based on the presently offered data, the 1- μ g examination does not offer much better diagnostic accuracy compared to the 250- μ g corticotropin examination [28] It needs to be noted that porcine ACTH is utilized in some countries, although the proof for its usage is much less than with artificial ACTH analogs such as cosyntropin [29].

- **Management approached to AI:**

Improved assay techniques show that daily physical production of cortisol, 5-6mg/ m² body area (BSA), is less than at first approximated [30]. Current suggestions for oral replacement doses of hydrocortisone are reduced at 10-12 mg/m² BSA, although numerous patients get greater comparable doses [30] Swedish patients with primary AI had more than a 2-fold rise in mortality compared with age-matched controls [31]. The excess fatalities resulted from cardio, transmittable as well as deadly illness, which might be attributable to supra-physiological glucocorticoid doses. Patients with secondary AI as well as hypopituitarism likewise have actually raised death [32]. Nevertheless there was no proof that patients with corticotroph deficiency requiring glucocorticoid therapy had greater mortality compared to those with various other pituitary hormonal shortages. (GH deficiency was not assessed in all patients and also might have been a confounding aspect) [32]. For that reason the excess mortality connected with hypopituitarism may not attributable to supra-physiological steroid application.

Glucocorticoid excess might lower bone mineral density (BMD). Løvas et al reported small reductions in BMD in patients with primary AI (as compared to a reference population, mean Z scores at femoral neck and lumbar spine varied from -0.57 to -0.17) [33]. Typically, the patients were taking more than suggested glucocorticoid dosages. These findings support recommendations to utilize lower dosages. Reduced flowing degrees of adrenal androgens could also add to the reduced bone mineral density seen in AI [34].

Preliminary glucocorticoid therapy provides excellent symptomatic renovation in AI. Patients taking chronic adrenal hormone replacement record decreased quality of life (QOL) contrasted with healthy and balanced controls [35]. Possible explanations consist of non-physiological glucocorticoid substitute and absence of adrenal androgen replacement. The observation that patients with primary as well as secondary adrenal insufficiency experience similar impairments [35] recommends that inappropriate mineralocorticoid replacement is unlikely to be the cause.

We currently cannot recreate the body clock of endogenous cortisol production. Normally cortisol levels come to a head prior to waking as well as fall to a low point during nighttime sleep [36]. Nevertheless, even three day-to-day doses of hydrocortisone could not approximate this rhythm, and also a current research reported no differences in QOL between two or 3 daily doses [37]. Another alternative is to utilize a longer acting glucocorticoid, such as prednisolone or prednisone, in an easier solitary morning dosage. No distinctions in QOL were reported between patients taking hydrocortisone or prednisolone in a research that did not deal with the impact of dosage equivalence [38].

Hydrocortisone management using a subcutaneous pump is a novel strategy for glucocorticoid replacement, with the prospective to give the morning cortisol rise. A complete day-to-day dose of 10mg/m² hydrocortisone restored typical

circadian rhythm in most patients [39] In a recent pilot research Harbeck et al. administered a solitary mixture of hydrocortisone from midnight to 0800h to 14 patients [40] 0800h cortisol degrees were regular to increased adhering to the mixture, however low a few weeks later. There were no differences between post-infusion as well as basal QOL or cognition steps, in addition to damaged memory in those with highest post-infusion cortisol levels. A larger research with longer treatment duration is should examine this method additionally. New hydrocortisone modified-release formulations, a prep work by DuoCort and Chronocort® (Phoqus Pharmaceuticals Ltd) are in development [41,42]. These formulations could offer more physiological pharmacokinetics with greater levels of cortisol on waking, as well as long-term researches of effects on QOL and various other specifications are awaited.

Dehydroepiandrosterone (DHEA) substitute continuously be questionable, with contrasting reports pertaining to quality of life [43,44] DHEA levels are low at birth, rise starting around age of 6-10 years, top around age 24 and also decline afterwards [45]. Some propose that DHEA insufficiency explains the impaired QOL in AI, particularly in ladies. Healthy and balanced guys acquire most androgens from the testes to make sure that the androgenic results of DHEA are most likely lesser.

A 50mg daily dose of DHEA has been reported to provide physical replacement [46] Alkatib et al. done a meta-analysis of 10 tests lasting three months or more, which evaluated QOL, anxiety, stress and anxiety as well as sexual function in grown-up women with primary or secondary adrenal insufficiency [47]. DHEA treatment could have a role in pubertal ladies, however. Binder et al. examined the impact of 25mg DHEA or sugar pill for 12 months in women of mean age 23 years (array 13-25) with additional adrenal insufficiency, two or more additional pituitary hormonal agent shortages, and a low DHEA level [48].

4. CONCLUSION

Adrenal insufficiency is a lethal problem; very strong research evidence suggests that long-lasting corticosteroid usage is consistently connected with gotten adrenal insufficiency. Measurement of cost-free lotion or salivary cortisol might be useful when CBG is reduced, but calls for standardization. Adrenal insufficiency is related to minimized quality of life that may be triggered by non-physiological glucocorticoid replacement. DHEA insufficiency is unlikely to play a major role in quality of life of adults, as well as regular replacement is not necessitated.

REFERENCES

- [1] Lovas K, Husebye E. High prevalence and increasing incidence of Addison's disease in western Norway. *Clin Endocrinol* 2002; 56: 781–91.
- [2] Erichsen MM, Lovas K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. *J Clin Endocrinol Metab* 2009; 94: 4882–90.
- [3] Tomlinson JW, Holden N, Hills R, et al. Association between premature mortality and hypopituitarism. *Lancet* 2001; 357: 425–31.
- [4] Mason AS, Meade TW, Lee JA, Morris JN. Epidemiological and clinical picture of Addison's disease. *Lancet* 1968; 2: 744–47.
- [5] Nerup J. Addison's disease—clinical studies. A report of 108 cases. *Acta Endocrinol (Copenh)* 1974; 76: 127–41.
- [6] Kong MF, Jeff coate W. Eighty-six cases of Addison's disease. *Clin Endocrinol (Oxf)* 1994; 41: 757–61.
- [7] Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. *Postgrad Med J* 1997; 73: 286–88.
- [8] Laureti S, Vecchi L, Santeusano F, Falorni A. Is the prevalence of Addison's disease underestimated? *J Clin Endocrinol Metab* 1999; 84: 1762.
- [9] Arlt W, Allolio B. Adrenal insufficiency. *Lancet* 2003; 361: 1881–93. 2 Bornstein SR. Predisposing factors for adrenal insufficiency. *N Engl J Med* 2009; 360: 2328–39.
- [10] Neary N, Nieman L. Adrenal insufficiency: etiology, diagnosis and treatment. *Curr Opin Endocrinol Diabetes Obes* 2010; 17: 217–23.
- [11] Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. *Postgrad Med J*. 1997;73:286–288.

- [12] Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. *J Clin Endocrinol Metab.* 2007;92:595–603.
- [13] Triolo TM, Baschal EE, Armstrong TK, et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. *J Clin Endocrinol Metab.* 2009;94:4517–4523.
- [14] Alizadeh BZ, Eerligh P, van der Slik AR, et al. MICA marks additional risk factors for Type 1 diabetes on extended HLA haplotypes: an association and meta-analysis. *Mol Immunol.* 2007;44:2806–2812.
- [15] Zake LN, Ghaderi M, Park YS, et al. MHC class I chain-related gene alleles 5 and 5.1 are transmitted more frequently to type 1 diabetes offspring in HBDI families. *Ann N Y Acad Sci.* 2002;958:309–311.
- [16] Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. *Nature.* 1993;361:726–730.
- [17] Bornstein SR. Predisposing factors for adrenal insufficiency. *N Engl J Med.* 2009;360:2328–2339.
- [18] Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. *Lancet.* 2009;374:293–300.
- [19] Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. *Oncologist.* 2007;12:107–113.
- [20] Kazlauskaitė R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. *J Clin Endocrinol Metab.* 2008;93:4245–4253.
- [21] Oelkers W, Boelke T, Bähr V. Dose-response relationships between plasma adrenocorticotropin (ACTH), cortisol, aldosterone, and 18-hydroxycorticosterone after injection of ACTH-(1–39) or human corticotropin-releasing hormone in man. *J Clin Endocrinol Metab.* 1988;66:181–186.
- [22] Lee MK, Vasikaran S, Doery JC, Wijeratne N, Prentice D. Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study. *Postgrad Med J.* 2013;89:617–620.
- [23] Wood JB, Frankland AW, James VH, Landon J. A rapid test of adrenocortical function. *Lancet.* 1965;1:243–245.
- [24] Abdu TA, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. *J Clin Endocrinol Metab.* 1999;84:838–843.
- [25] Chatha KK, Middle JG, Kilpatrick ES. National UK audit of the short synacthen test. *Ann Clin Biochem.* 2010;47:158–164.
- [26] Reynolds RM, Stewart PM, Seckl JR, Padfield PL. Assessing the HPA axis in patients with pituitary disease: a UK survey. *Clin Endocrinol (Oxf).* 2006;64:82–85.
- [27] Grinspoon SK, Biller BM. Clinical review 62: Laboratory assessment of adrenal insufficiency. *J Clin Endocrinol Metab.* 1994;79:923–931.
- [28] Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. *Ann Intern Med.* 2003;139:194–204.
- [29] Gundgurthi A, Garg MK, Dutta MK, Pakhetra R. Intramuscular ACTH stimulation test for assessment of adrenal function. *J Assoc Physicians India.* 2013;61:320–324.
- [30] Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. *J Clin Endocrinol Metab.* 1991;72:39–45.
- [31] 25. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. *J Clin Endocrinol Metab.* 2006;91:4849–4853.
- [32] 26. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism West Midlands Prospective Hypopituitary Study Group. *Lancet.* 2001;357:425–431.

- [33] 27. Lovas K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. *Eur J Endocrinol*. 2009;160:993–1002.
- [34] 28. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. *J Clin Endocrinol Metab*. 2008;93:400–409.
- [35] Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. *J Clin Endocrinol Metab*. 2007;92:3912–3922.
- [36] Weitzman ED, Fukushima D, Nogeire C, et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. *J Clin Endocrinol Metab*. 1971;33:14–22.
- [37] 31. Bleicken B, Hahner S, Loeffler M, et al. Influence of hydrocortisone dosage scheme on health related quality of life in patients with adrenal insufficiency. *Clin Endocrinol (Oxf)* 2009 Mar 28; E-pub ahead of print.
- [38] Bleicken B, Hahner S, Loeffler M, et al. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. *Eur J Endocrinol*. 2008;159:811–817.
- [39] Lovas K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. *Eur J Endocrinol*. 2007;157:109–112.
- [40] Harbeck B, Kropp P, Monig H. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study. *Appl Psychophysiol Biofeedback*. 2009;34:113–119.
- [41] Lennernas H, Skrtic S, Johannsson G. Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. *Expert Opin Drug Metab Toxicol*. 2008;4:749–758.
- [42] Verma S, Vanryzin C, Sinai N, et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) versus conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. *Clin Endocrinol (Oxf)* 2009 May 25.
- [43] Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. *N Engl J Med*. 1999;341:1013–1020.
- [44] Lovas K, Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. *J Clin Endocrinol Metab*. 2003;88:1112–1118.
- [45] Orentreich N, Brind JL, Rizer RL, Vogelmann JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *J Clin Endocrinol Metab*. 1984;59:551–555.
- [46] Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. *J Clin Endocrinol Metab*. 1998;83:1928–1934.
- [47] Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. *J Clin Endocrinol Metab*. 2009;94:3676–3681.
- [48] Binder G, Weber S, Ehrismann M, et al. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. *J Clin Endocrinol Metab*. 2009;94:1182–1190.